enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Hold” from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have been given a consensus rating of “Hold” by the fourteen brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $11.0455.

A number of equities analysts have recently commented on the company. Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $7.00 to $4.00 in a research note on Friday, May 8th. Guggenheim downgraded enGene from a “buy” rating to a “neutral” rating in a research note on Thursday, May 7th. WBB Securities initiated coverage on enGene in a report on Monday, April 13th. They issued a “buy” rating and a $21.50 target price on the stock. Weiss Ratings downgraded enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 15th. Finally, Citizens Jmp lowered enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th.

Get enGene alerts:

View Our Latest Stock Analysis on ENGN

Hedge Funds Weigh In On enGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its position in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Siren L.L.C. raised its position in shares of enGene by 57.5% during the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after buying an additional 1,916,895 shares during the last quarter. Cormorant Asset Management LP raised its position in shares of enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after buying an additional 1,676,405 shares during the last quarter. Blue Owl Capital Holdings LP lifted its stake in shares of enGene by 2.5% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock valued at $30,349,000 after buying an additional 82,831 shares during the period. Finally, Braidwell LP lifted its stake in shares of enGene by 38.2% in the fourth quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after buying an additional 865,000 shares during the period. Institutional investors own 64.16% of the company’s stock.

enGene Price Performance

Shares of enGene stock opened at $1.79 on Wednesday. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The firm has a fifty day simple moving average of $1.78 and a 200-day simple moving average of $5.48. The stock has a market capitalization of $119.91 million, a price-to-earnings ratio of -0.82 and a beta of -0.28. enGene has a 1-year low of $1.40 and a 1-year high of $12.25.

enGene (NASDAQ:ENGN – Get Free Report) last announced its earnings results on Monday, June 15th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. During the same quarter in the prior year, the company posted $0.51 earnings per share. On average, sell-side analysts expect that enGene will post -1.84 earnings per share for the current year.

enGene Company Profile

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Featured Articles

• Five stocks we like better than enGene
• System Upgrade: First Internet Bancorp Options Surge
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market
• Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter

Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.